Dassault Systèmes acquired U.S.-based Medidata, major player in information technologies for clinical trials, for $5.5 billion. This represents to date the largest buyout in the emerging area of in silico medicine and in silico trials and a significant milestone to address the complexity of developing personalied medicine and patient-centric experiences.
Dassault Systèmes aims to reinforce its position as a scientific company by providing the life sciences industry with an integrated business experience platform for an end-to-end approach to research and discovery, development, clinical testing, manufacturing and commercialisation of new therapies and health technologies.
Dassault Systèmes’ 3DEXPERIENCE platform offers its clients 3D visualisation technology to simulate the lifecycle of a new product. By acquiring Medidata’s artificial intelligence (AI) platform, which handles clinical development, commercial, and real-world data for the life sciences industry, Dassault is planning to accelerate developments in personalised health.
“There are few more concrete signs that an emerging industrial sector is consolidating than when such large buyouts occur. In Silico Medicine in general, and In Silico Trials in particular are in my opinion the most exciting news in the biomedical industry in the last 10 years” says our President, Prof Marco Viceconti.
The official press release can be found here
